- Trial phase
- Approved
- Time to market
- Already approved and commercialized (FDA approved May 2021). Under the CorMedix asset purchase agreement, ZYNRELEF will transfer to CorMedix upon deal close, expected Q1 2027.
- Why 4/10
- ZYNRELEF is already FDA-approved and commercially marketed with no pending PDUFA, pivotal readout, or AdComm in the next 12 months. The next hard catalyst is the closing of the CorMedix asset sale (expected Q1 2027), but M&A is excluded from impact scoring per the rubric. As an approved drug with no pending regulatory binary, the impact score is capped at 3-5.
ZYNRELEF is now part of the asset sale to CorMedix (CRMD), expected to close in Q1 2027. For HRTX shareholders, the stock is transitioning into a stub: Heron will retain CRMD shares, net operating loss carryforwards (~$2.3B), and earn-out rights. The next event is the shareholder vote and regulatory clearance for the sale. For investors tracking ZYNRELEF specifically, watch CorMedix's commercial execution post-close and any label expansion efforts under new ownership.
Price Chart
Executive Summary
ZYNRELEF (bupivacaine/meloxicam) is an FDA-approved non-opioid extended-release injection for postoperative pain management, developed by Heron Therapeutics (HRTX). First approved in May 2021 with a label expansion in January 2024, it is one of four commercial-stage products Heron is selling to CorMedix Therapeutics (CRMD) in a deal announced November 9, 2026, valued at approximately $223M upfront plus earn-outs. ZYNRELEF revenue grew 13.8% YoY in Q3 2026, but Heron's overall revenue declined 7.8% amid a CINVANTI patent loss and strategic reset. The asset sale is expected to close in Q1 2027, after which CorMedix will commercialize ZYNRELEF alongside its other hospital products.
How It Works
ZYNRELEF is a fixed-dose combination of two drugs in one injection: bupivacaine, a local anesthetic that numbs the area by blocking nerve signals, and meloxicam, a non-steroidal anti-inflammatory drug (NSAID) that reduces inflammation and pain. It is administered as a single dose into the surgical site during a procedure and uses Heron's Biochronomer technology to release the drugs slowly over approximately 72 hours, providing extended pain relief without the need for opioids.
Trial Status
ZYNRELEF is FDA-approved for management of postoperative pain for up to 72 hours in adults. The indication was expanded in January 2024 to include additional orthopedic and soft tissue procedures. It also received European Commission authorization in September 2020.
The Two-Sided Case
Upcoming Catalysts
- Closing of CorMedix asset acquisition (expected Q1 2027) - shareholder vote and regulatory clearances
- CorMedix integration and commercial execution for ZYNRELEF post-close
- Potential label expansion or new clinical data under CorMedix ownership
Source Filing
The SecBot filing or press-release report that triggered this drug report:
HERON THERAPEUTICS, INC. /DE/ DEFA14A HRTX ·Originating report